Advertisement
Screener

ANIXA BIOSCIENCES, INC. (ANIX) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

2.8 / 5 stars · 68/120 Roast Me

ANIXA BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

ANIXA BIOSCIENCES, INC. (ANIX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 75.70% for the 12-month period ending 2025-10-31, per its 10-K filed 2026-01-12.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-01-12

  • ANIXA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2015-07-31 was 117.80%, a 2.35% increase year-over-year.
  • ANIXA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2015-04-30 was 116.60%, a 0.00% change year-over-year.
  • ANIXA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2015-01-31 was 114.30%, a 0.95% decline year-over-year.
  • ANIXA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2014-07-31 was 115.10%.
  • ANIXA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 75.70%, a 1.05% decline from fiscal 2024.
  • ANIXA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 76.50%, a 23.71% decline from fiscal 2023.
  • ANIXA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 100.27%, a 2.39% decline from fiscal 2022.
  • ANIXA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 102.72%, a 5.78% decline from fiscal 2021.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month as first filed
2025-10-3175.70%
10-K · filed 2026-01-12
2024-10-3176.50%
10-K · filed 2026-01-12
76.48%
10-K · filed 2025-01-10
2023-10-31100.27%
10-K · filed 2025-01-10
2022-10-31102.72%
10-K · filed 2024-01-16
2021-10-31109.02%
10-K · filed 2023-01-04
2020-10-31114.22%
10-K · filed 2022-01-04
2019-10-31116.72%
10-K · filed 2021-01-07
2018-10-31124.94%
10-K · filed 2020-01-09
2017-10-31119.20%
10-K · filed 2019-01-11
2016-10-31181.10%
10-K · filed 2018-01-09
2015-10-31117.80%
10-K · filed 2016-12-08
2015-07-31117.80%
10-Q · filed 2015-08-18
114.80%
10-Q · filed 2015-08-18
2015-04-30116.60%
10-Q · filed 2015-05-22
114.30%
10-Q · filed 2015-05-22
2015-01-31114.30%
10-Q · filed 2015-03-09
2014-10-31115.30%
10-K · filed 2015-12-23
2014-07-31115.10%
10-Q · filed 2015-08-18
115.40%
10-Q · filed 2015-08-18
2014-04-30116.60%
10-Q · filed 2014-06-16
115.60%
10-Q · filed 2015-05-22
2014-01-31115.40%
10-Q · filed 2015-03-09
2013-10-31116.50%
10-K · filed 2015-01-29
2013-07-31116.50%
10-Q · filed 2014-09-15
2013-04-30117.00%
10-Q · filed 2014-06-16
116.50%
10-Q · filed 2014-06-16
2013-01-31115.70%
10-Q · filed 2014-03-17
2012-10-31109.00%
10-K/A · filed 2014-01-17
2012-07-31124.00%
10-Q/A · filed 2013-09-20
2012-04-30125.00%
10-Q/A · filed 2013-06-19
124.00%
10-Q/A · filed 2013-06-19
2012-01-31124.00%
10-Q/A · filed 2013-03-25
2011-07-31105.00%
10-Q · filed 2012-09-14
102.00%
10-Q · filed 2012-09-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
CITIUS ONCOLOGY, INC. (CTOR)United States$0.097B-1.49
Milestone Pharmaceuticals Inc. (MIST)$0.098B-2.00
Acrivon Therapeutics, Inc. (ACRV)United States$0.091B-1.03
ProMIS Neurosciences Inc. (PMN)$0.102B
Rallybio Corp (RLYB)United States$0.089B
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
ONCOLYTICS BIOTECH INC (ONCY)$0.086B
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)United States$0.086B
Biomea Fusion, Inc. (BMEA)United States$0.107B-3.30
Lexaria Bioscience Corp. (LEXX)$0.084B-1.92